| 2023-10-31 | +22.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2023-10-13 | -21.6% | legal | SEC EDGAR | HRMY 8-K: 8.01 and (SEC Filing) |
| 2023-01-06 | -18.7% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-05-03 | -18.6% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-19 | -17.8% | news | Zacks Investment Research | Zacks.com featured highlights include Harmony Biosciences, Tripadvisor, The AES and Concentrix - Zacks Investment Research |
| 2022-11-01 | +15.4% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-09-24 | -14.9% | news | Seeking Alpha | Harmony Bio slips on late-stage trial setback for Fragile X syndrome therapy |
| 2025-09-24 | -14.9% | earnings | Investing.com | Harmony Biosciences stock falls after Phase 3 trial misses endpoint - Investing.com |
| 2025-10-23 | +13.7% | earnings | Seeking Alpha | Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance |
| 2025-10-23 | +13.7% | legal | SEC EDGAR | HRMY 8-K: 2.02 and (SEC Filing) |
| 2025-10-23 | +13.7% | earnings | TradingView | Harmony Biosciences Q3 2025 Financial Results - TradingView |
| 2025-05-06 | +12.0% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-05-02 | +11.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-03-24 | -8.5% | legal | SEC EDGAR | HRMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-11-03 | +8.5% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. Q3 2025 Earnings Preview |
| 2024-08-06 | +8.3% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-21 | +7.9% | news | Zacks | Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last? |
| 2026-04-21 | +7.9% | legal | Seeking Alpha | Harmony Bio spikes after new Wakix patent litigation |
| 2026-04-21 | +7.9% | news | Seeking Alpha | Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond |
| 2026-04-21 | +7.9% | news | Seeking Alpha | Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond (NASDAQ:HRMY) - Seeking Alpha |
| 2026-04-21 | +7.9% | news | ChartMill | HRMY Stock Chart | HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - ChartMill |
| 2026-04-21 | +7.9% | news | GuruFocus | Harmony Biosciences (HRMY) Sees Share Price Increase in Midday T - GuruFocus |
| 2026-04-21 | +7.9% | legal | Seeking Alpha | Harmony Bio after new Wakix patent litigation (HRMY:NASDAQ) - Seeking Alpha |
| 2026-04-21 | +7.9% | analyst | Stocktwits | HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits |
| 2026-04-21 | +7.9% | news | GuruFocus | Harmony Biosciences (HRMY) Shares Rise on Positive Patent Litiga - GuruFocus |
| 2026-04-21 | +7.9% | legal | GuruFocus | Harmony Biosciences (HRMY) Secures Patent Lawsuit Against Generi - GuruFocus |
| 2025-11-04 | +7.7% | earnings | Seeking Alpha | Harmony Biosciences raises 2025 revenue outlook to $845M-$865M amid record WAKIX patient growth and advancing pipeline |
| 2025-11-04 | +7.7% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | +7.7% | earnings | Seeking Alpha | Harmony Biosciences beats top-line and bottom-line estimates; raises FY25 outlook |
| 2025-11-04 | +7.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-04 | +7.7% | earnings | Quiver Quantitative | HARMONY BIOSCIENCES Earnings Results: $HRMY Reports Quarterly Earnings - Quiver Quantitative |
| 2022-02-28 | +7.4% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-13 | +7.3% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-12 | -7.2% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-18 | -7.1% | news | Yahoo Finance | Will Pediatric Cataplexy Approval for WAKIX Expand Harmony Biosciences Holdings' (HRMY) Rare-Disease Narrative? - Yahoo Finance |
| 2023-10-11 | -6.8% | legal | SEC EDGAR | HRMY 8-K: 2.01, 7.01 (SEC Filing) |
| 2023-08-01 | -6.3% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-12-03 | +5.8% | analyst | Investing.com | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com |
| 2024-04-30 | +5.4% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-08-02 | +5.4% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-10-29 | -5.3% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-09-25 | -5.2% | legal | SEC EDGAR | HRMY 8-K: 1.01 and (SEC Filing) |
| 2024-05-03 | -4.8% | legal | SEC EDGAR | HRMY 8-K: 5.02 and (SEC Filing) |
| 2021-08-11 | +4.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-05-11 | +4.2% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-03-29 | +4.1% | legal | SEC EDGAR | HRMY 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | -4.0% | news | Business Wire | Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-23 | -4.0% | news | Business Wire | Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire |
| 2026-04-23 | -4.0% | news | simplywall.st | Is It Time To Revisit Harmony Biosciences Holdings (HRMY) After Its Recent Share Price Rebound? - simplywall.st |
| 2026-04-23 | -4.0% | analyst | GuruFocus | Harmony Biosciences (HRMY) Attracts Buy Rating Amid IP Litigatio - GuruFocus |
| 2023-02-21 | -3.9% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-11 | -3.9% | news | Yahoo Finance | Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Yahoo Finance |
| 2023-08-14 | +3.7% | legal | SEC EDGAR | HRMY 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-02-22 | -3.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-11-08 | -3.6% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-11-20 | +3.5% | earnings | simplywall.st | A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb - simplywall.st |
| 2025-10-27 | -3.5% | news | Seeking Alpha | Harmony Biosciences: Performing Commercially But Competition Afoot |
| 2025-10-27 | -3.5% | news | Seeking Alpha | Harmony Biosciences: Performing Commercially But Competition Afoot (NASDAQ:HRMY) - Seeking Alpha |
| 2026-02-24 | +3.3% | earnings | Seeking Alpha | Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline |
| 2026-02-24 | +3.3% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript |
| 2026-02-24 | +3.3% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-24 | +3.3% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. Non-GAAP EPS of $0.57 misses by $0.50, revenue of $243.78M beats by $3.46M |
| 2026-02-24 | +3.3% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-02-24 | +3.3% | earnings | Yahoo Finance | Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates - Yahoo Finance |
| 2026-02-24 | +3.3% | earnings | Quiver Quantitative | HARMONY BIOSCIENCES ($HRMY) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2026-02-24 | +3.3% | news | simplywall.st | Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential - simplywall.st |
| 2026-02-24 | +3.3% | earnings | Investing.com | Earnings call transcript: Harmony Bio misses Q4 2025 EPS estimates - Investing.com |
| 2026-02-24 | +3.3% | news | Stock Titan | Harmony Biosciences (Nasdaq: HRMY) grows 2025 sales, targets $1B WAKIX in 2026 - Stock Titan |
| 2026-02-24 | +3.3% | earnings | Business Wire | Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion - Business Wire |
| 2026-02-24 | +3.3% | earnings | Investing.com | Harmony Biosciences misses Q4 earnings despite revenue beat - Investing.com |
| 2026-02-24 | +3.3% | news | TipRanks | Why Harmony Biosciences Stock Is Quietly Surging - TipRanks |
| 2026-02-24 | +3.3% | legal | TradingView | Harmony Biosciences Holdings, Inc. SEC 10-K Report - TradingView |
| 2026-02-01 | +3.1% | executive | The Motley Fool | Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity - The Motley Fool |
| 2025-08-20 | +3.1% | analyst | Seeking Alpha | Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug |
| 2025-08-20 | +3.1% | analyst | Seeking Alpha | Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug (HRMY) - Seeking Alpha |
| 2026-02-23 | -3.0% | analyst | Seeking Alpha | Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades |
| 2026-02-23 | -3.0% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Preview |
| 2026-02-23 | -3.0% | news | Yahoo Finance | How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks - Yahoo Finance |
| 2026-02-23 | -3.0% | analyst | Investing.com | Deutsche Bank cuts Harmony Biosciences stock rating on patent risk - Investing.com |
| 2026-02-23 | -3.0% | analyst | Seeking Alpha | Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades - Seeking Alpha |
| 2026-02-23 | -3.0% | analyst | GuruFocus | Harmony Biosciences (HRMY) Faces Downgrades Amid Legal Concerns - GuruFocus |
| 2026-02-02 | +3.0% | news | Seeking Alpha | Harmony Biosciences Makes The Grade |
| 2026-02-02 | +3.0% | news | Seeking Alpha | Harmony Biosciences Makes The Grade (NASDAQ:HRMY) - Seeking Alpha |
| 2026-02-02 | +3.0% | executive | Yahoo Finance | CFO’s Full Share Exit Contrasts With Harmony’s Positive WAKIX Growth Story - Yahoo Finance |
| 2025-10-09 | +2.9% | news | Moomoo | Take Care Before Jumping Onto Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Even Though It's 26% Cheaper - Moomoo |
| 2026-02-25 | +2.8% | earnings | simplywall.st | Harmony Biosciences (HRMY) Margin Compression In FY 2025 Tests Bullish Profitability Narrative - simplywall.st |
| 2026-02-13 | +2.8% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment - ChartMill |
| 2025-08-05 | -2.7% | earnings | Seeking Alpha | Harmony targets $1B+ WAKIX sales in narcolepsy as late-stage pipeline advances |
| 2025-08-05 | -2.7% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-05 | -2.7% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript |
| 2025-08-05 | -2.7% | earnings | Seeking Alpha | Harmony Biosciences misses top-line and bottom-line estimates; reaffirms FY25 outlook |
| 2025-08-05 | -2.7% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-09-25 | +2.7% | analyst | Seeking Alpha | Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade |
| 2025-09-25 | +2.7% | news | Yahoo Finance | HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal - Yahoo Finance |
| 2025-09-25 | +2.7% | analyst | Seeking Alpha | Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - Seeking Alpha |
| 2026-02-17 | -2.7% | earnings | Seeking Alpha | Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy |
| 2026-02-17 | -2.7% | earnings | Yahoo Finance | Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline - Yahoo Finance |
| 2026-02-17 | -2.7% | legal | Seeking Alpha | Harmony Bio wins FDA label expansion for Wakix (HRMY:NASDAQ) - Seeking Alpha |
| 2026-02-17 | -2.7% | news | simplywall.st | Harmony Biosciences Gains Pediatric WAKIX Approval As Valuation Draws Attention - simplywall.st |
| 2024-11-01 | +2.7% | legal | SEC EDGAR | HRMY 8-K: 8.01 and (SEC Filing) |
| 2025-10-16 | -2.6% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY): A Growth Stock with a Promising Technical Setup - ChartMill |
| 2026-04-08 | +2.4% | legal | Stock Titan | HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-02-16 | +2.4% | news | Yahoo Finance | 3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY) - Yahoo Finance |
| 2023-05-31 | -2.4% | legal | SEC EDGAR | HRMY 8-K: 5.02 (SEC Filing) |
| 2025-12-01 | +2.3% | analyst | Investing.com | Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com |
| 2026-02-26 | +2.3% | analyst | Finviz | Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Finviz |
| 2026-01-20 | +2.2% | executive | Investing.com | Harmony Biosciences CFO Kapadia sells $752k in stock - Investing.com |
| 2026-01-14 | +2.0% | news | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2021-11-22 | -2.0% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-01-28 | -2.0% | analyst | Seeking Alpha | Harmony Biosciences: Still Undervalued But Unappealing Risk/Reward (Downgrade) |
| 2026-01-28 | -2.0% | executive | Investing.com | Sandip Kapadia, Harmony Biosciences CFO, sells $139k in HRMY stock - Investing.com |
| 2026-01-28 | -2.0% | analyst | Seeking Alpha | Harmony Biosciences: Still Undervalued But Unappealing Risk/Reward (Downgrade) - Seeking Alpha |
| 2026-01-28 | -2.0% | news | The Motley Fool | How Harmony Biosciences Can Prove Its Skeptics Wrong - The Motley Fool |
| 2026-01-06 | +1.9% | earnings | DirectorsTalk Interviews | Harmony Biosciences Holdings (HRMY) Stock Analysis: A Revenue Growth Powerhouse with 25.66% Upside Potential - DirectorsTalk Interviews |
| 2026-01-06 | +1.9% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case - ChartMill |
| 2025-08-02 | +1.8% | news | Yahoo Finance | Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals? - Yahoo Finance |
| 2026-01-27 | -1.8% | news | Yahoo Finance | Evaluating Harmony Biosciences (HRMY) Valuation After Stronger Fundamentals And Breakout Signals - Yahoo Finance |
| 2026-01-27 | -1.8% | earnings | The Motley Fool | Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - The Motley Fool |
| 2026-03-28 | +1.7% | earnings | AD HOC NEWS | Harmony Biosciences stock faces headwinds amid analyst downgrade and Q4 earnings miss - AD HOC NEWS |
| 2025-02-25 | -1.6% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-19 | +1.5% | news | Yahoo Finance | Are Options Traders Betting on a Big Move in Harmony Biosciences Stock? - Yahoo Finance |
| 2026-04-02 | -1.5% | executive | Business Wire | Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board |
| 2026-04-02 | -1.5% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-02 | -1.5% | executive | Business Wire | Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board - Business Wire |
| 2026-04-02 | -1.5% | executive | Stock Titan | Harmony Biosciences (HRMY) names new COO and reshapes its board - Stock Titan |
| 2026-04-02 | -1.5% | executive | TipRanks | Harmony Biosciences Appoints Peter Anastasiou as Chief Operating Officer - TipRanks |
| 2025-11-05 | +1.4% | earnings | Seeking Alpha | Harmony Biosciences Holdings, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-05 | +1.4% | earnings | Yahoo Finance | Harmony Biosciences Holdings Inc (HRMY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance |
| 2025-10-29 | -1.4% | news | Yahoo Finance | Harmony Biosciences (HRMY): Assessing Valuation After Recent Share Price Fluctuations - Yahoo Finance |
| 2024-07-01 | -1.4% | legal | SEC EDGAR | HRMY 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-14 | -1.4% | executive | MT Newswires | Harmony Biosciences Names Glenn Reicin as Finance Chief |
| 2026-04-14 | -1.4% | executive | Business Wire | Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer |
| 2026-04-14 | -1.4% | news | MarketBeat | Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference |
| 2026-04-14 | -1.4% | news | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript |
| 2026-04-14 | -1.4% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-14 | -1.4% | executive | Stock Titan | New CFO arrives as Harmony sticks to $1B-plus 2026 sales target - Stock Titan |
| 2026-04-14 | -1.4% | earnings | Stock Titan | New Harmony Biosciences (NASDAQ: HRMY) CFO as 2026 WAKIX revenue view held - Stock Titan |
| 2026-01-26 | +1.4% | news | Yahoo Finance | Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance |
| 2026-01-26 | +1.4% | news | The Motley Fool | I Was Shocked to Find This Value-Priced Biotech Growth Stock - The Motley Fool |
| 2026-01-26 | +1.4% | news | Yahoo Finance | HRMY or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance |
| 2026-01-26 | +1.4% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup - ChartMill |
| 2022-10-03 | +1.4% | legal | SEC EDGAR | HRMY 8-K: 8.01 (SEC Filing) |
| 2026-04-19 | -1.3% | news | Cổng thông tin điện tử Tỉnh Sơn La | Harmony (HRMY) Stock: What Experts Say (Breakout Watch) 2026-04-18 - Expert Breakout Alerts - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-18 | -1.3% | earnings | simplywall.st | A Look At Harmony Biosciences (HRMY) Valuation After New CFO Appointment And Reaffirmed 2026 Revenue Guidance - simplywall.st |
| 2025-09-05 | -1.3% | news | Seeking Alpha | Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript |
| 2023-03-10 | -1.2% | legal | SEC EDGAR | HRMY 8-K: 8.01 (SEC Filing) |
| 2021-11-09 | +1.2% | legal | SEC EDGAR | HRMY 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-16 | +1.2% | news | Business Wire | Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting |
| 2026-04-16 | +1.2% | earnings | Stock Titan | Rare epilepsy drug data from Harmony heads to neurology meeting - Stock Titan |
| 2023-07-27 | -1.1% | legal | SEC EDGAR | HRMY 8-K: 1.01, 1.02, 7.01 (SEC Filing) |
| 2023-10-04 | -1.1% | legal | SEC EDGAR | HRMY 8-K: 8.01 and (SEC Filing) |
| 2024-04-11 | +1.1% | legal | SEC EDGAR | HRMY 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-02-10 | -1.0% | news | Business Wire | Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Business Wire |
| 2026-04-09 | +1.0% | news | Stock Titan | Harmony Biosciences (HRMY) CCO RSUs Vest; 3,173 Shares Withheld for Taxes - Stock Titan |
| 2026-04-06 | -0.9% | news | Stock Titan | Harmony Biosciences (HRMY) director granted 17,710 stock options at $27.74 strike - Stock Titan |
| 2026-04-06 | -0.9% | executive | Stock Titan | Harmony Biosciences (HRMY) awards 212,241 stock options to COO Anastasiou - Stock Titan |
| 2026-04-06 | -0.9% | news | Stock Titan | Harmony Biosciences (HRMY) director Troy Ignelzi files initial Form 3 - Stock Titan |
| 2023-09-14 | -0.9% | legal | SEC EDGAR | HRMY 8-K: 1.01 and (SEC Filing) |
| 2023-10-05 | +0.8% | legal | SEC EDGAR | HRMY 8-K: 5.02 and (SEC Filing) |
| 2025-07-23 | -0.8% | analyst | Yahoo Finance | Harmony Biosciences Advances Pipeline While Navigating Analyst Caution - Yahoo Finance |
| 2026-04-13 | -0.8% | executive | simplywall.st | Will Harmony’s New COO and Board Reboot Change Harmony Biosciences Holdings' (HRMY) Narrative? - simplywall.st |
| 2021-06-15 | -0.8% | legal | SEC EDGAR | HRMY 8-K: 5.02 (SEC Filing) |
| 2026-04-22 | -0.8% | news | Stock Titan | HRMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan |
| 2026-04-22 | -0.8% | analyst | Investing.com Nigeria | Oppenheimer raises Harmony Biosciences stock price target on patent strength - Investing.com Nigeria |
| 2026-04-22 | -0.8% | earnings | simplywall.st | Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed? - simplywall.st |
| 2026-04-22 | -0.8% | news | StreetInsider | Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $72 at Oppenheimer - StreetInsider |
| 2023-01-23 | -0.8% | legal | SEC EDGAR | HRMY 8-K: 5.02 and (SEC Filing) |
| 2023-01-23 | -0.8% | legal | SEC EDGAR | HRMY 8-K: 5.02 (SEC Filing) |
| 2025-06-05 | +0.7% | news | Seeking Alpha | Harmony Biosciences: If It Ain't Broke |
| 2025-06-05 | +0.7% | expansion | Seeking Alpha | Harmony Biosciences, Lupin reach agreement on Wakix generic launch |
| 2025-06-05 | +0.7% | legal | SEC EDGAR | HRMY 8-K: 8.01 and (SEC Filing) |
| 2026-03-04 | +0.7% | news | Business Wire | Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire |
| 2024-01-08 | +0.6% | legal | SEC EDGAR | HRMY 8-K: 2.02 and (SEC Filing) |
| 2026-04-17 | -0.6% | earnings | MarketBeat | Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat |
| 2025-12-22 | +0.6% | news | Trefis | Is Harmony Biosciences Stock Built to Withstand More Downside? - Trefis |
| 2026-04-04 | -0.6% | executive | Simply Wall St. | Harmony Biosciences Holdings (HRMY) Valuation After New COO And Board Appointments |
| 2026-04-04 | -0.6% | executive | Quiver Quantitative | Harmony Biosciences Holdings, Inc. ($HRMY) CEO 2025 Pay Revealed - Quiver Quantitative |
| 2026-04-03 | -0.6% | executive | Yahoo Finance | Harmony Biosciences Holdings (HRMY) Valuation After New COO And Board Appointments - Yahoo Finance |
| 2026-04-03 | -0.6% | news | Stock Titan | Executive pay and board elections at Harmony Biosciences (HRMY) 2026 virtual meeting - Stock Titan |
| 2023-04-24 | -0.5% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-04-03 | +0.4% | legal | SEC EDGAR | HRMY 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-01-29 | -0.4% | news | Yahoo Finance | Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance |
| 2026-03-31 | +0.3% | news | Stock Titan | Needham healthcare conference to feature Harmony chat on April 13 - Stock Titan |
| 2026-01-09 | +0.2% | news | Yahoo Finance | Is Harmony Biosciences (HRMY) Pricing Reflect Future Growth After Recent Mixed Share Performance - Yahoo Finance |
| 2026-01-09 | +0.2% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy - ChartMill |
| 2026-02-12 | -0.1% | analyst | Yahoo Finance | Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade - Yahoo Finance |
| 2026-02-27 | -0.1% | analyst | Yahoo Finance | Harmony Biosciences Downgrades Put Wakix Patent Risks In Sharp Focus - Yahoo Finance |
| 2025-10-20 | -0.0% | news | ChartMill | Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case - ChartMill |
| 2026-04-24 | — | news | Simply Wall St. | Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations |
| 2026-04-24 | — | earnings | Simply Wall St. | Why Harmony Biosciences (HRMY) Reaffirmed 2026 Revenue Guidance and Hired a Markets-Focused CFO |
| 2026-04-24 | — | news | Yahoo Finance | Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance |
| 2026-04-24 | — | earnings | Yahoo Finance | Why Harmony Biosciences (HRMY) Reaffirmed 2026 Revenue Guidance and Hired a Markets-Focused CFO - Yahoo Finance |